This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Trichuris Suis Ova Treatment in Left-sided Ulcerative Colitis

This study has been terminated.
(MFR's business decision to d/c TSO production -unrelated to any safety concern.)
Sponsor:
Collaborators:
Coronado Biosciences, Inc.
Autoimmunity Centers of Excellence
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT01953354
First received: September 24, 2013
Last updated: February 9, 2017
Last verified: February 2017
September 24, 2013
February 9, 2017
November 2013
November 2015   (Final data collection date for primary outcome measure)
Percentage of Participants Who Achieved a Clinical Response at Week 12 [ Time Frame: Week 12 ]
Clinical response is defined as a reduction in the Mayo score of at least 3 points and at least a 30% reduction from Baseline, along with either a decrease from Baseline in the rectal bleeding subscore of more than 1 point or a rectal bleeding subscore of 0 or 1.
Percentage of Subjects who Achieve a Clinical Response [ Time Frame: 12 Weeks ]
Clinical response will be defined as a reduction in Mayo score of ≥ 3 and ≥ 30% reduction from baseline, along with either a decrease from baseline in rectal bleeding sub-score of > 1 point or absolute rectal bleeding score of 0 or 1.
Complete list of historical versions of study NCT01953354 on ClinicalTrials.gov Archive Site
  • Percent of Participants Who Achieved Remission at Week 12 [ Time Frame: Week 12 ]
    Remission is defined as a Mayo score of less than or equal to 1 with absence of rectal bleeding and endoscopy score of 0 or 1.
  • Percent of Participants With Healed Colonic Mucosa at Week 12 [ Time Frame: Week 12 ]
    Healed colonic mucosa is defined as a Mayo endoscopy score of 0 or 1.
  • Percent of Participants With a Modified Clinical Response [ Time Frame: From Day 0 through time of first clinical response or end of follow-up, whichever comes first, up to 12 Weeks ]
    Modified clinical response is defined as a reduction in the modified Mayo score (i.e., minus the endoscopy component) of at least 2 points from baseline.
  • Time to Modified Clinical Response [ Time Frame: From Baseline through the day that modified clinical response is reached. Week 16 is the last visit that the modified Mayo score is assessed. ]
    Number of days to reach a modified clinical response. Modified clinical response is defined as a reduction in the modified Mayo score (i.e., minus the endoscopy component) of at least 2 points from baseline.
  • Percent of Participants With Colonoscopic Evidence of Visible Worm [ Time Frame: From Day 0 through end of follow-up, up to 36 weeks ]
    Stool evaluations for ova and parasites confirmed the absence of T. suis. If evidence suggested a presence of T. suis, a colonoscopy would be performed to confirm invasion with a visible worm.
  • Percent of Participants With Increase in Diarrhea [ Time Frame: From Day 0 through end of follow-up, up to 36 weeks ]
    An increase in diarrhea is defined as an increase in the Mayo Score's Stool Frequency score by at least 1 point from baseline at any time during follow-up.
  • Percent of Participants With Increase in Concurrent Ulcerative Colitis (UC) Medications or New Rescue Medications Added [ Time Frame: From Day 0 through Week 16 ]
    New or increase in UC medications is defined as a need for dose-escalation of concurrent medications or need for rescue medications to treat UC through Week 16.
  • Percentage of Subjects in Each Study Arm Achieving Remission [ Time Frame: 12 Weeks ]
    Percentage of subjects in each study arm who achieve a remission at Week 12, where remission is defined as Mayo score of ≤ 1 with absence of rectal bleeding and endoscopy score of 0 or 1.
  • Percentage of Subjects in Each Study Arm with Healed Colonic Tissue [ Time Frame: 12 Weeks ]
    Percentage of subjects in each study arm with healed colonic mucosa at Week 12, where healed colonic mucosa is defined as a Mayo endoscopy score of 0 or 1.
  • Time to Reach a Modified Clinical Response [ Time Frame: Up to 12 Weeks ]
    Time to reach a modified clinical response, where modified clinical response is defined as a reduction in the modified Mayo score of ≥ 2 from baseline (i.e., minus the endoscopy component).
  • Percentage of Subjects Each Study Arm with Colonoscopic Evidence of a Visible Worm (luminal or attached) [ Time Frame: Baseline to Week 36 ]
  • Percentage of Subjects Each Study Arm with Increase in Diarrhea [ Time Frame: Baseline to Week 36 ]
    The percentage of subjects experiencing an increase in diarrhea, as measured by the Mayo Score's Stool Frequency score.
  • Percentage of Subjects in Each Study Arm Requiring Increased Medications to Treat UC [ Time Frame: Baseline to Week 36 ]
    Percentage of subjects who require dose-escalation of concurrent medications or need rescue medications to treat UC.
Not Provided
Not Provided
 
Trichuris Suis Ova Treatment in Left-sided Ulcerative Colitis
A Prospective, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study of Trichuris Suis Ova Treatment in Left-sided Ulcerative Colitis and Its Effects on Mucosal Immune State and Microbiota
The purpose of this study is to evaluate the safety and effectiveness of trichuris suis ova (TSO) in ulcerative colitis (UC). We will look at how TSO affects the body's immune response and if there are related changes in participants' UC.

The cause of UC, an inflammatory bowel disease (IBD), is not well understood. It is believed to be caused from an abnormal immune response to the normal bacteria that live in the gut (intestines and colon). This response acts as an "attack" on the healthy tissue of the bowel by a person's own immune cells which leads to disease.

It is well known that autoimmune diseases such as IBD, asthma, diabetes, and multiple sclerosis are more common in industrialized, well-developed countries with better sanitation and hygiene, as in the United States. These "cleaner" environments reduce exposure to germs and parasites naturally found in the environment. This reduced exposure may trigger responses in the body that make people more prone to diseases such as UC. People in non-industrialized countries and the tropics, where parasites are common, rarely develop these diseases. This observation has led researchers to want to better understand the relationship between the lack of natural bacteria in the gut and the onset of autoimmune diseases like as UC.

Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Investigator
Primary Purpose: Treatment
Colitis, Ulcerative
  • Biological: Trichuris suis ova (TSO)
    Six doses of TSO orally over a ten-week period (e.g., every 2 weeks x 10 weeks for a total of 6 total doses)
    Other Names:
    • T. suis ova
    • 7500 Trichuris suis ova (7500 TSO )
    • CNDO 201
  • Biological: Placebo
    Six doses of TSO placebo orally over a ten-week period (e.g., every 2 weeks x 10 weeks for a total of 6 total doses)
    Other Name: Trichuris suis ova (TSO) placebo
  • Experimental: Trichuris suis ova (TSO)
    Six doses of TSO orally over a ten-week period
    Intervention: Biological: Trichuris suis ova (TSO)
  • Placebo Comparator: Placebo
    Six doses of TSO placebo orally over a ten-week period
    Intervention: Biological: Placebo

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
16
November 2015
November 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Subject has provided written informed consent
  2. Diagnosis of UC (newly diagnosed or established patients) as determined by medical history, endoscopic and histological confirmation with the proximal disease extent limited to the left colon (distal to the splenic flexure), and accessible by flexible sigmoidoscopy. Patients with left-sided disease and the presence of a periappendiceal red patch (limited cecal inflammation) will be eligible as long as there is no intervening evidence of colitis between the cecal base and the upper boundary of inflammation in the left colon.
  3. Mayo score >/= 4, as scored at Screen 2
  4. If taking the following medications at Screen 1, subjects must meet the following criteria:

    1. Oral Corticosteroids: stable treatment for at least 4 weeks prior to Day 0 with a maximum dose equivalent to <\=15 mg/day of prednisone
    2. Immunosuppressants (azathioprine (AZA) or 6-mercaptopurine (6-MP)): treatment for at least 12 weeks with a stable dose, not exceeding 2.5 mg/kg/day of AZA or 1.5 mg/kg/day of 6-MP, during the 4 weeks prior to Day 0
    3. Aminosalicylates: stable oral doses up to 4.8 g/day for at least 4 weeks prior to Day 0.

Exclusion Criteria:

  1. Subjects whose UC is anticipated to require surgical, endoscopic, or radiologic intervention during study participation
  2. Uncontrolled GI bleeding
  3. Subjects who have disease limited to the rectum (maximum disease extent of less than 15 cm)
  4. Women who are pregnant, breast-feeding, or planning to become pregnant during the study. All women of childbearing potential must have a negative serum pregnancy test at Screen 2 prior to randomization of treatment.
  5. Women of childbearing potential not using adequate birth control measures (e.g., total abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, surgical sterilization, Depo-Provera, or hormonal implants).
  6. Current or recent serious systemic disorder including clinically significant impairment in cardiac, pulmonary, liver, renal, endocrine, hematologic, or neurologic function, based on investigator discretion
  7. Subjects currently receiving the following concomitant medications:

    1. Prednisone or its equivalent at unstable doses or at doses exceeding 15 mg/day within 4 weeks prior to Day 0
    2. Local steroids such as budesonide, Colifoam, or Predsol enemas within 2 weeks prior to Screen 2
    3. Topical therapies, either mesalamine or steroids, taken within 2 weeks of Screen 2
    4. Non-steroidal anti-inflammatory drugs (NSAIDs), Cyclooxygenase (COX)-2 inhibitors, or aspirin >100 mg/day within 2 weeks prior to Screen 2
    5. Tumor necrosis factor (TNF)-alpha inhibitors including but not limited to infliximab (Remicade) or adalimumab (Humira) within 12 weeks of Day 0
    6. Any biological agent within 12 weeks of Day 0
    7. Metronidazole within 4 weeks of Day 0
    8. Receipt of any investigational agent within the 12 weeks prior to Day 0
    9. Antibacterial or oral antifungal agents within 4 weeks of Screen 2
    10. Interferon (IFN) therapy
    11. Anticoagulants
    12. Methotrexate
  8. Blood transfusion within the 12 weeks prior to Day 0
  9. Presence of any of the following abnormal laboratory parameters at Screen 1:

    1. Hemoglobin < 10.0 g/dL
    2. White Blood Count (WBC) < 4,000 or > 20,000/L (equivalent to WBC < 4 or > 20 x109/L)
    3. Platelets < 100,000 or > 800,000/L (equivalent to platelets < 100 or > 800 x109/L)
    4. Total bilirubin > 1.5 × Upper limit of normal (ULN)
    5. Alanine transaminase (ALT) > 2 × ULN
    6. Aspartate transaminase (AST) > 2 × ULN
    7. Alkaline phosphatase (ALK) > 1.5 × ULN
    8. Gamma-glutamyl transferase (GGT) > 1.5 × ULN
    9. Creatinine > 1.5 × ULN
  10. History of drug or alcohol abuse within one year prior to Day 0
  11. Inability to understand the nature and requirements of the study, or to comply with the study procedures or planned schedule of study visits
  12. Evidence of infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
  13. Active infection with C. difficile, bacterial enteric pathogens, or pathogenic ova/parasites
  14. History of malignancy within the last 5 years, except for resected basal or squamous cell carcinoma, treated cervical dysplasia, or treated in situ cervical cancer Grade I
  15. History of colonic dysplasia
  16. Any social or medical condition that, in the opinion of the investigator, would preclude provision of informed consent, make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.
Sexes Eligible for Study: All
18 Years to 70 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01953354
DAIT AUC02
Yes
Not Provided
Not Provided
Not Provided
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
  • Coronado Biosciences, Inc.
  • Autoimmunity Centers of Excellence
Study Chair: Stephen Hanauer, MD Northwestern University
Study Chair: Bana Jabri, MD, PhD University of Chicago
National Institute of Allergy and Infectious Diseases (NIAID)
February 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP